MAGEA10
Melanoma-associated antigen 10
Also known as: CT1.10, MAGAA_HUMAN, MAGE10, MGC10599
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P43363
- Gene
- MAGEA10
- Ensembl
- ENSG00000124260
- Chromosome
- X
- Canonical length
- 369 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the downstream melanoma antigen family A, 5 (MAGEA5) gene.[provided by RefSeq, Oct 2011]
Canonical amino-acid sequenceUniProt
369 residues, UniProt reviewed canonical sequence.
>P43363|MAGEA10
1 MPRAPKRQRC MPEEDLQSQS ETQGLEGAQA PLAVEEDASS STSTSSSFPS SFPSSSSSSS
61 SSCYPLIPST PEEVSADDET PNPPQSAQIA CSSPSVVASL PLDQSDEGSS SQKEESPSTL
121 QVLPDSESLP RSEIDEKVTD LVQFLLFKYQ MKEPITKAEI LESVIRNYED HFPLLFSEAS
181 ECMLLVFGID VKEVDPTGHS FVLVTSLGLT YDGMLSDVQS MPKTGILILI LSIVFIEGYC
241 TPEEVIWEAL NMMGLYDGME HLIYGEPRKL LTQDWVQENY LEYRQVPGSD PARYEFLWGP
301 RAHAEIRKMS LLKFLAKVNG SDPRSFPLWY EEALKDEEER AQDRIATTDD TTAMASASSS
361 ATGSFSYPELocalizationUniProt · AlphaFold · HPA
Whether an antibody against MAGEA10 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.45
- Highest tissue expression
- 8.9 nTPM
Expression across tissuesHPA
Tissue
- placenta: 8.9 nTPM
- testis: 2.4 nTPM
- skin: 0.4 nTPM
- bone marrow: 0.2 nTPM
- lymph node: 0.2 nTPM
- adrenal gland: 0.1 nTPM
Single-cell type
- adipocytes: 0.8 nCPM
- early spermatids: 0.3 nCPM
- early primary spermatocytes: 0.1 nCPM
- late primary spermatocytes: 0.1 nCPM
- late spermatids: 0.1 nCPM
- oligodendrocyte progenitor cells: 0.1 nCPM
Immune cell
- basophil: 0.5 nTPM
- neutrophil: 0.4 nTPM
- NK-cell: 0.2 nTPM
- classical monocyte: 0.1 nTPM
- eosinophil: 0.1 nTPM
- intermediate monocyte: 0.1 nTPM
Brain region
- cerebellum: 2.4 nTPM
- white matter: 2.4 nTPM
- cerebral cortex: 2.3 nTPM
- pons: 2.3 nTPM
- basal ganglia: 2.1 nTPM
- hippocampal formation: 2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MAGEA10.
Disease | ImmuneIEDB
Conditions an epitope on MAGEA10 was assayed in.
- melanoma T cell
- skin melanoma T cell
ReferencesPubMed · IEDB
Publications for MAGEA10 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Diagnostic performance of anti-MAGEA family protein autoantibodies in esophageal squamous cell carcinoma.
2023 · Int Immunopharmacol · RCR 0.5 · 4 citations - Serum cancer testis antigen MAGEA3-IgG serves as a diagnostic biomarker in lung adenocarcinoma.
2026 · Clin Transl Oncol
Reference: T cellIEDB
6 publications
- Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma.
2021 · J Immunother Cancer · RCR 2.2 · 45 citations - Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma.
2021 · Cancer Immunol Res · RCR 1.6 · 32 citations - TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
2023 · J Immunother Cancer · RCR 1 · 12 citations - Methionine oxidation selectively enhances T cell reactivity against a melanoma antigen.
2023 · iScience · RCR 0.6 · 5 citations - Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
2020 · Elife · RCR 0.6 · 17 citations
Show 1 more
- Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
2022 · Front Immunol · RCR 0.2 · 3 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD missense Z
- 0.31
- DepMap mean gene effect
- 0.09
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MAGEA10 as an antibody target. Whether an autoantibody or antibody against MAGEA10 could matter depends on whether native MAGEA10 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MAGEA10 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MAGEA10 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...